$0.26
2.24% today
Nasdaq, Jun 28, 07:20 pm CET
ISIN
US75973T1016
Symbol
RNLX

Renalytix Plc - ADR Share price

$0.26
-0.17 39.08% 1M
-0.24 47.72% 6M
-0.13 33.56% YTD
-1.76 87.14% 1Y
-30.31 99.15% 3Y
-13.24 98.08% 5Y
-13.24 98.08% 10Y
Nasdaq, Closing price Thu, Jun 27 2024
ISIN
US75973T1016
Symbol
RNLX

Key figures

Market capitalization $20.00m
Enterprise Value $24.72m
PER (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 11.14
P/S ratio (TTM) P/S ratio 9.01
P/B ratio (TTM) P/B ratio negative
Sales growth (TTM) Sales growth -40.23%
Turnover (TTM) Turnover $2.22m
EBIT (operating result TTM) EBIT $-33.29m
Free cash flow (TTM) Free cash flow $-30.92m
Cash position $4.70m
EPS (TTM) EPS $-0.78
P/E ratio expected negative
P/S ratio expected 2.32
EV/Sales expected 2.87
Short interest 1.52%
Show more

Is Renalytix Plc - ADR a top scorer stock according to the dividend, high growth investing or Leverman strategy?

As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.

Renalytix Plc - ADR Share analysis

Unlock scores for free

Analyst opinions

3 Analysts have issued a Renalytix Plc - ADR forecast:

3x Buy
100%

Analyst opinions

3 Analysts have issued a Renalytix Plc - ADR forecast:

Buy
100%

Financial data from Renalytix Plc - ADR

Profit and loss account P&L | Balance sheet | Cash flow


Quarter TTM Annually
Mar '24
+/-
%
2.22 2.22
40% 40%
100%
- Direct costs 2.26 2.26
20% 20%
102%
-0.03 -0.03
103% 103%
-1%
- Selling and administrative expenses 21 21
33% 33%
961%
- Research and development costs 12 12
16% 16%
518%
-33 -33
27% 27%
-1,481%
- Depreciation and amortization 0.42 0.42
19% 19%
19%
EBIT (operating result) EBIT -33 -33
27% 27%
-1,500%
Net profit -37 -37
5% 5%
-1,689%

Figures in millions USD.

Don't miss a thing! We will send you all news about the Renalytix Plc - ADR share directly to your mailbox free of charge.

If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.

Renalytix Plc - ADR Share News

Neutral
GlobeNewsWire
about 19 hours ago
Throughout the hearings process and pending the Panel's decision, the Company's ADSs will continue trading on The Nasdaq Global Market under the symbol “RNLX” Throughout the hearings process and pending the Panel's decision, the Company's ADSs will continue trading on The Nasdaq Global Market under the symbol “RNLX”
Neutral
GlobeNewsWire
14 days ago
Company has Achieved Prerequisites for Growing Test Adoption with FDA Authorization, Clinical Outcomes Data, Inclusion in Clinical Guidelines, and Broad Insurance Coverage Company has Achieved Prerequisites for Growing Test Adoption with FDA Authorization, Clinical Outcomes Data, Inclusion in Clinical Guidelines, and Broad Insurance Coverage
Neutral
Seeking Alpha
about one month ago
Renalytix Plc (NASDAQ:RNLX ) Q3 2024 Results Conference Call May 15, 2024 8:30 AM ET Company Participants Peter DeNardo - CapComm Partners James McCullough - Chief Executive Officer James Sterling - Chief Financial Officer Howard Doran - Chief Business Officer Conference Call Participants Dan Arias - Stifel Randy Baron - Pinnacle Associates Mark Massaro - BTIG Jens Lindqvist - Investec Operator...
More Renalytix Plc - ADR News

Company profile

Renalytix Plc manufactures medical devices and equipment. It offers artificial intelligence for kidney disease. The company was founded by James McCullough on March 15, 2018 and is headquartered in Penarth, the United Kingdom.

Head office United Kingdom
CEO James McCullough
Founded 2018
Website www.renalytixai.com

Register for free

StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.

The Apple share at a glance with charts, current key figures, news and share analyses.
The best dividend stocks in the dividend top scorer list.
Stock analyses of the best stocks worldwide.
Build wealth now